You are here: Home » PTI Stories » National » News
Business Standard

Natco Pharma gets USFDA nod for Armodafinil tablets

Press Trust of India  |  New Delhi 

Drug firm has received the final approval from the US health regulator for generic Armodafinil tablets, used as wakefulness promoting agent, and plans to launch the product immediately in the US.

The company has received final approval from the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets in the strengths of 50 mg, 150 mg and 250 mg, said in a filing to BSE.



The company's abbreviated new drug application (ANDA) contains a paragraph IV certification, it added.

"Natco and its marketing partner Breckenridge Pharmaceutical Inc plan to launch this product in market immediately," said.

Cephalon sells the product in three strengths under the brand name 'Nuvugil', it added.

According to IMS health, Nuvugil tablets had US sales of around USD 480 million for twelve months ending December 2015, said.

Nuvugil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work disorder.

Shares of were today trading 1.76 per cent down at Rs 601.35 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Natco Pharma gets USFDA nod for Armodafinil tablets

Drug firm Natco Pharma has received the final approval from the US health regulator for generic Armodafinil tablets, used as wakefulness promoting agent, and plans to launch the product immediately in the US. The company has received final approval from the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets in the strengths of 50 mg, 150 mg and 250 mg, Natco Pharma said in a filing to BSE. The company's abbreviated new drug application (ANDA) contains a paragraph IV certification, it added. "Natco and its marketing partner Breckenridge Pharmaceutical Inc plan to launch this product in USA market immediately," Natco Pharma said. Cephalon sells the product in three strengths under the brand name 'Nuvugil', it added. According to IMS health, Nuvugil tablets had US sales of around USD 480 million for twelve months ending December 2015, Natco Pharma said. Nuvugil is indicated to improve wakefulness in adult patients with excessive sleepiness ... Drug firm has received the final approval from the US health regulator for generic Armodafinil tablets, used as wakefulness promoting agent, and plans to launch the product immediately in the US.

The company has received final approval from the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets in the strengths of 50 mg, 150 mg and 250 mg, said in a filing to BSE.

The company's abbreviated new drug application (ANDA) contains a paragraph IV certification, it added.

"Natco and its marketing partner Breckenridge Pharmaceutical Inc plan to launch this product in market immediately," said.

Cephalon sells the product in three strengths under the brand name 'Nuvugil', it added.

According to IMS health, Nuvugil tablets had US sales of around USD 480 million for twelve months ending December 2015, said.

Nuvugil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work disorder.

Shares of were today trading 1.76 per cent down at Rs 601.35 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Natco Pharma gets USFDA nod for Armodafinil tablets

Drug firm has received the final approval from the US health regulator for generic Armodafinil tablets, used as wakefulness promoting agent, and plans to launch the product immediately in the US.

The company has received final approval from the US Food and Drug Administration (USFDA) for generic version of Armodafinil tablets in the strengths of 50 mg, 150 mg and 250 mg, said in a filing to BSE.

The company's abbreviated new drug application (ANDA) contains a paragraph IV certification, it added.

"Natco and its marketing partner Breckenridge Pharmaceutical Inc plan to launch this product in market immediately," said.

Cephalon sells the product in three strengths under the brand name 'Nuvugil', it added.

According to IMS health, Nuvugil tablets had US sales of around USD 480 million for twelve months ending December 2015, said.

Nuvugil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy, or shift work disorder.

Shares of were today trading 1.76 per cent down at Rs 601.35 apiece on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard